Get started
Author

Anja Williams

Combined inhibition of CXCL12 and PD-1 in MSS colorectal and pancreatic cancer: modulation of the microenvironment and clinical effects
2021 · Meggy Suarez-Carmona, Anja Williams, et al. · Journal for ImmunoTherapy of Cancer · 85
PDF
Functional imaging and circulating biomarkers of response to regorafenib in treatment-refractory metastatic colorectal cancer patients in a prospective phase II study
2017 · Khurum Khan, Mihaela Rata, et al. · Gut · 73
PDF
Trastuzumab Deruxtecan with Nivolumab in HER2-Expressing Metastatic Breast or Urothelial Cancer: Analysis of the Phase Ib DS8201-A-U105 Study
2024 · Erika Hamilton, Matthew D. Galsky, et al. · Clinical Cancer Research · 69
Cytokine release syndrome-like serum responses after COVID-19 vaccination are frequent and clinically inapparent under cancer immunotherapy
2022 · Thomas Walle, Sunanjay Bajaj, et al. · Nature Cancer · 24
PDF
Pseudoprogression on treatment with immune-checkpoint inhibitors in patients with gastrointestinal malignancies: Case series and short literature review
2019 · Vasiliki Michalarea, Elisa Fontana, et al. · Current Problems in Cancer · 19
Phase 1 safety and efficacy of IMC-F106C, a PRAME × CD3 ImmTAC bispecific, in post-checkpoint cutaneous melanoma (CM).
2024 · Omid Hamid, Anja Williams, et al. · Journal of Clinical Oncology · 18
PDF
A first-in-human phase 1 trial of nx-1607, a first-in-class oral CBL-B inhibitor, in patients with advanced solid tumor malignancies.
2022 · Adam Sharp, Anja Williams, et al. · Journal of Clinical Oncology · 13
1537P Phase I/II study with CXCL12 inhibitor NOX-A12 and pembrolizumab in patients with microsatellite-stable, metastatic colorectal or pancreatic cancer
2020 · N. Halama, A. Williams, et al. · Annals of Oncology · 10
PET-Negative Gastrointestinal Stromal Tumors
2013 · Anja Williams, Andreas Gutzeit, et al. · Case Reports in Oncology · 9
PDF
Abstract CT117: Phase 1/2 study with CXCL12 inhibitor NOX-A12 and pembrolizumab in patients with microsatellite-stable, metastatic colorectal or pancreatic cancer
2020 · Niels Halama, Anja Williams, et al. · Cancer Research · 8
Safety and Activity of Fibroblast Growth Factor Receptor Inhibitors in Advanced Malignancies: A Pooled Analysis of Early-Phase Clinical Trials
2025 · Rafael Grochot, Kroopa Joshi, et al. · JCO Precision Oncology · 7
PDF
A Phase I Dose Escalation and Cohort Expansion Study of CB307, a Trispecific Humabody against PSMA, CD137, and Albumin in Patients with PSMA-Positive Solid Tumors
2025 · Johann S. de Bono, Anja Williams, et al. · Clinical Cancer Research · 7
A First-in-Human Phase 1 Trial of NX-1607, a First-in-Class Oral CBL-B Inhibitor, in Patients with Advanced Malignancies Including DLBCL
2023 · Graham P. Collins, William Townsend, et al. · Blood · 7
Abstract CT217: An open-label, Phase I/IIa study of VB10.NEO (DIRECT-01) in combination with checkpoint blockade in patients with locally advanced or metastatic solid tumors including melanoma, NSCLC, renal cell carcinoma, urothelial cancer or SSCHN
2019 · Jurgen Krauss, Angela Krackhardt, et al. · Cancer Research · 6
First-in-human phase 1/2a study of the first-in-class, next-generation CDK4-selective inhibitor PF-07220060 + endocrine therapy (ET): Updated safety data in patients with HR+/HER2− mBC.
2024 · Antonio Giordano, Manish Sharma, et al. · Journal of Clinical Oncology · 5
PDF
Abstract PD18-05: MEN1611, a PI3K inhibitor, combined with trastuzumab ± fulvestrant for HER2+/PIK3CA mutant advanced or metastatic breast cancer: updated safety and efficacy results from the ongoing phase 1b study (B-PRECISE-01)
2023 · Martine Piccart, Audrey Hennequin, et al. · Cancer Research · 3
Ctni-49. Early Signal of Activity From a Phase 2 Study of St101, a First-in-class Peptide Antagonist of Ccaat/enhancer-binding Protein Β (c/ebpβ), in Recurrent Glioblastoma (gbm)
2022 · Fabio Iwamoto, Vinai Gondi, et al. · Neuro-Oncology · 3
PDF
694 Phase 1 safety and efficacy of brenetafusp, a PRAME × CD3 ImmTAC bispecific, in post-checkpoint cutaneous melanoma (CM)
2024 · Diwakar Davar, Anja Williams, et al. · Journal for ImmunoTherapy of Cancer · 2
Abstract CT286: TILVANCE-301, a phase 3 study of lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in combination with pembrolizumab vs pembrolizumab alone in treatment-naive unresectable or metastatic melanoma
2024 · Sajeve Thomas, Young Ki Hong, et al. · Cancer Research · 2
Author Correction: Cytokine release syndrome-like serum responses after COVID-19 vaccination are frequent and clinically inapparent under cancer immunotherapy
2022 · Thomas Walle, Sunanjay Bajaj, et al. · Nature Cancer · 2
PDF
Hierarchical classification of immune cell transcriptomes at population-scale
2026 · Christopher Beltz, Zekai Qiu, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 1
Outcomes of patients (pts) with metastatic colorectal cancer (mCRC) participating in phase I clinical trials: The Sarah Cannon Research Institute UK experience.
2023 · Ekaterina Ignatova, Elisa Fontana, et al. · Journal of Clinical Oncology · 1
PDF
777 Initial clinical characterization of novel proximal biomarkers for NX-1607, a first-in-class oral CBL-B inhibitor, in patients with advanced malignancies
2022 · Sarah Whelan, Christopher Karim, et al. · Journal for ImmunoTherapy of Cancer · 1
PDF
Abstract CT207: A phase 1 open-label, dose escalation and expansion trial to investigate the safety, pharmacokinetics and pharmacodynamics of CB307, a Trispecific Humabody® T-cell enhancer, in patients with PSMA+ advanced and/or metastatic solid tumors (POTENTIA)
2022 · Johann S. de Bono, Hendrik-Tobias Arkenau, et al. · Cancer Research · 1
OVM-200, a recombinant overlapping peptide vaccine, breaks immune tolerance to survivin in patients with advanced solid tumours: a multicentre, open-label, dose-expansion, phase 1 study
2026 · Peter Kok-Ting Wan, Thomas Morris, et al. · medRxiv
Works count: 35
Citation count: 376
H-index: 9
I10-index: 8
Year
Topic
Type